English  |  正體中文  |  简体中文  |  Items with full text/Total items : 12145/12927 (94%)
Visitors : 911879      Online Users : 1006
RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
Scope Tips:
  • please add "double quotation mark" for query phrases to get precise results
  • please goto advance search for comprehansive author search
  • Adv. Search
    HomeLoginUploadHelpAboutAdminister Goto mobile version
    Please use this identifier to cite or link to this item: http://ir.nhri.org.tw/handle/3990099045/13253


    Title: Impact of efavirenz mid-dose plasma concentration on long-term weight change among virologically suppressed people living with HIV
    Authors: Huang, SH;Huang, WC;Lin, SW;Chuang, YC;Sun, HY;Chang, SY;Kuo, PH;Wu, PY;Liu, WC;Chiang, C;Hung, CC;Chang, SC
    Contributors: Institute of Population Health Sciences
    Abstract: BACKGROUND: Pharmacogenetic studies have shown that slow and intermediate metabolizers of efavirenz (EFV) gained less weight compared to extensive metabolizers. It is hypothesized that increased EFV exposure suppresses weight gain. We investigated the effect of EFV mid-dose plasma concentration (C12) on long-term weight change among virologically suppressed people living with HIV (PLWH). METHODS: Participants in a prospective EFV pharmacokinetic study were included if they had been taking EFV-containing combination antiretroviral therapy for more than 240 weeks and had three or more weight measurements. The weight changes and time to ≥5% of weight gain over 192 weeks were compared between PLWH with higher and those with lower EFV C12 (using mean population C12 as the cutoff). EFV C12 and CYP2B6 516G>T polymorphism were examined in generalized estimating equations (GEE) and in a Cox proportional hazards model for associations with weight gain, after adjustments for age, sex, companion antiretroviral agent, CD4 lymphocyte count, and plasma HIV RNA. RESULTS: One-hundred and eighteen PLWH were included. PLWH with higher EFV C12 had less mean weight gain compared to those with lower C12 after 192 weeks (-0.09 kg vs +1.58 kg, p = 0.033). PLWH with higher C12 were less likely to gain ≥5% weight in Kaplan-Meier analysis (p = 0.0003). In both GEE and Cox proportional hazards models, a higher EFV C12 was associated with less weight gain, while CYP2B6 516G>T was not, after adjustments made for confounding factors. CONCLUSION: Our findings support that increased EFV exposure was associated with less weight gain.
    Date: 2021-06-01
    Relation: Journal of Acquired Immune Deficiency Syndromes. 2021 Jun 01;87(2):834-841.
    Link to: http://dx.doi.org/10.1097/qai.0000000000002650
    JIF/Ranking 2023: http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=1525-4135&DestApp=IC2JCR
    Cited Times(WOS): https://www.webofscience.com/wos/woscc/full-record/WOS:000753305800015
    Cited Times(Scopus): https://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85106666786
    Appears in Collections:[其他] 期刊論文

    Files in This Item:

    File Description SizeFormat
    PUB33587507.pdf324KbAdobe PDF178View/Open


    All items in NHRI are protected by copyright, with all rights reserved.

    Related Items in TAIR

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - Feedback